Novo Nordisk has launched its once-daily Wegovy weight-loss pill in the US at a lower price than injections.
The drug is the first and only GLP-1 pill on the market and was approved shortly before Christmas.
Cash-paying patients can access the starting dose for $149 a month, far below injectable prices.
The pill offers a needle-free option and is expected to broaden patient appeal.
Novo aims to regain market share amid strong competition from Eli Lilly.
Shares rose after the launch despite a sharp yearly decline.
The pill is available through major US pharmacies and telehealth providers.
UK approval is under review and a decision is expected later this year.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Price War
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
Add A Comment